UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

The Lancet

Volumn 345, Issue 8962, 1995, Pages 1392-1397

  Allan, N C ^a   Shepherd, P C A ^a   Richards, S M ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAN1 INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; HYDROXYUREA; SULFONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029041749     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)92596-1     Document Type: Article

References (21)

1. Clinical investigation of human leukocyte interferon in chronic myelogenous leukaemia
2. Clinical investigation of human alpha interferon in chronic myeloid leukaemia
3. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia
4. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukaemia and implications for graft-versus leukaemic effect a review of recent results
5. Results of treatment of Ph'+chronic myelogenous leukaemia with an intensive treatment regimen (L-5 protocol)
6. Busulphan and bone marrow depression
7. Chronic granulocytic leukaemia with Ph' negative cells in bone marrow and a ten year remission after busulphan hypoplasia
8. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia a study of 82 patients treated with intermittent or daily administration
9. Interferon alpha-2b in acute- and chronic-phase chronic myelogenous leukaemia initial response and long-term results in 54 patients
10. The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects
11. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic meyloid leukemia
12. Myleran in chronic myeloid leukaemia. Results of treatment
13. Remisson induction in chronic granulocytic leukaemia using intermittent high dose busulphan
14. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension: results from MRC CML II Trial comparing busulphan with busulphan and thioguanine
15. Hydroxyurea therapy in chronic myelogenous leukemia
16. Prognostic discriminaton in "good-risk" chronic granulocytic leukemia
17. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and Examples
18. Evaluation of response time data involving transient states an illustration using heart-transplatation data
19. Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph-negative peripheral stem cells
20. Chronic myelogenous leukemia: a concise update
21. Standardization of Interferons